ASCENT

NCT02574455 📎

Regimen

Experimental
Sacituzumab govitecan-hziy 10 mg/kg IV D1, D8 Q3W until progression or toxicity.
Control
Single-agent treatment of physician's choice: eribulin, vinorelbine, capecitabine, or gemcitabine.

Population

Metastatic triple-negative breast cancer (excluding brain metastases in primary analysis) previously treated with >=2 prior lines of chemotherapy including a taxane.

Key finding

ASCENT established sacituzumab govitecan as standard of care in pretreated metastatic TNBC (NCCN category 1 preferred >=2L; FDA approved April 2021). First TROP2 ADC with OS benefit in any tumor.

Source: PMID 33882206

Timeline

  • Publication: 2021 Apr 22

Guideline citations

  • NCCN BREAST